Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers
Authors:
- Semih BaşcıSBSemih Başcı
- Naim AtaNANaim Ata
- Fevzi AltuntaşFAFevzi Altuntaş
- Tuğçe Nur YiğenoğluTYTuğçe Nur Yiğenoğlu
- Mehmet Sinan DalMDMehmet Sinan Dal
- Serdal KorkmazSKSerdal Korkmaz
- Sinem NamdaroğluSNSinem Namdaroğlu
- Abdülkadir BaştürkABAbdülkadir Baştürk
- Tuba HacıbekiroğluTHTuba Hacıbekiroğlu
- Mehmet Hilmi DoğuMDMehmet Hilmi Doğu
- İlHami BerberIBİlHami Berber
- Kürşat DalKDKürşat Dal
- 10 June 2021
- journal article
- research article
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 17 (1) , 135-139
Abstract
Previous studies reported that COVID-19 patients with cancer had higher rates of severe events such as intensive care unit (ICU) admission, mechanical ventilation (MV) assistance, and death during the COVID-19 course compared to the general population. However, no randomized study compared the clinical course of COVID-19 in patients with hematologic cancers to patients with solid cancers. Thus, in this study, we intend to reveal the outcome of COVID-19 in hematologic cancer patients and compare their outcomes with COVID-19 patients with solid cancers. The data of 926 laboratory-confirmed COVID-19 patients, including 463 hematologic cancer patients and an age-gender paired cohort of 463 solid cancer patients, were investigated retrospectively. The frequencies of severe and critical disease, hospital and ICU admission, MV assistance were significantly higher in hematologic cancer patients compared with the solid cancer patients (p = 0.001, p = 0.045, p = 0.001, and p = 0.001, respectively). The hospital stay was longer in patients with hematologic cancers (p = 0.001); however, the median ICU stay was 6 days in both groups. The case fatality rate (CFR) was 14.9% in patients with hematologic cancers, and it was 4.8% in patients with solid cancers, and there was a statistically significant difference regarding CFR between groups (p = 0.001). Our study revealed that COVID-19 patients with hematologic cancers have a more aggressive course of COVID-19 and have higher CFR compared to COVID-19 patients with solid cancers and support the increased susceptibility of patients with hematologic cancers during the outbreak.Keywords
This publication has 14 references indexed in Scilit:
- Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital SystemCancer Discovery, 2020
- Survival study of hospitalised patients with concurrent COVID‐19 and haematological malignanciesBritish Journal of Haematology, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 OutbreakCancer Discovery, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common GoalJournal of the National Comprehensive Cancer Network, 2020
- Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, ChinaAnnals of Oncology, 2020
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020
- A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family clusterThe Lancet, 2020
- Statistical power analyses using G*Power 3.1: Tests for correlation and regression analysesBehavior Research Methods, 2009